Highest-materiality recent filing
Reverse stock split from 1:2 to 1:10 approved, board to set ratio within one year.
cbdMD buys Bluebird Botanicals CBD e-commerce assets for 425k shares plus 525k earnout
Acquired substantially all assets of Gaia Botanicals d/b/a Bluebird Botanicals: brand, domain, trademarks, inventory.
cbdMD regains NYSE American compliance; BC indicator removed Dec 8, 2025
Received NYSE American letter Dec 5, 2025 confirming compliance with Sections 1003(a)(i) and (ii).
cbdMD Q4 net sales up 3-5% YoY; FY net loss improves to ~$2M from $3.7M
Net sales for fiscal 2025 expected $19.1–19.3M vs $19.5M prior year.
cbdMD converts all Series A Preferred to common, effects 1-for-8 reverse stock split
All 5,000,000 outstanding 8% Series A Preferred shares automatically converted into 65,000,000 common shares on May 6, 2025.
cbdMD shareholders approve automatic conversion of Series A Preferred Stock into common at 13:1
Shareholders approved automatic conversion of each Series A Preferred share into 13 common shares, eliminating $6.7M in accrued dividends and $4M annual dividend obligations.
cbdMD fully converts remaining $56K senior secured notes to equity, now debt-free
Remaining $56,000 Senior Secured Convertible Notes converted to common stock on Jan 14, 2025.
cbdMD reduces convertible note debt to $56K; issued 609K shares; Q1 cash ~$2.1M
Convertible note principal reduced to ~$56,000 as holders converted ~$309,000 principal plus accrued interest.
cbdMD receives additional NYSE American noncompliance notice for equity under $2M
Stockholders' equity $1,963,417 as of Sep 30, 2024, below $2M threshold; losses in 4 of 5 recent fiscal years.
cbdMD gets NYSE American plan acceptance for listing; equity at $3.1M, deadline Dec 2025
NYSE American accepted cbdMD's plan to regain compliance; plan period through Dec 5, 2025.
cbdMD acquires 'CBD MD' trademark from Majik Medicine for cash/stock; settles litigation
Paid $100k cash on closing; will pay $50k annually for 4 years ($300k total) and issued 75k shares of common stock (50k more in year 2).
cbdMD receives NYSE American acceptance of compliance plan; faces Dec 5, 2025 deadline
Stockholders' deficit of $3.1M as of March 31, 2024; non-compliance with $4M equity requirement.
cbdMD settles former office lease, expects ~$780K in total gains
Paid $255K to satisfy all past due obligations under former lease; mutual release executed.
Stockholders' equity was $3.1M as of March 31, 2024, below $4M minimum required by Section 1003(a)(ii).
Bradley Whitford appointed Chief Accounting Officer, Treasurer, Secretary; annual base salary $200,000.
cbdMD enters forbearance on sublease default, moves executive offices
Behind on rent since Sep 2023; default notice and summary ejectment filed Feb 2024.
cbdMD raises $1.25M via convertible notes with 8% interest, automatic conversion price adjustments
Gross proceeds $1.25M; aggregate principal $1.54M due to original issue discount.
cbdMD suspends Series A Preferred dividend, proposes mandatory conversion to common shares
Monthly cash dividend on 8% Series A Preferred suspended starting Aug 31, 2023 to conserve cash.
cbdMD completes 1-for-45 reverse stock split effective April 24, 2023
Reverse split ratio of 1:45 effective 12:01 a.m. ET on April 24, 2023, as approved by shareholders on Feb 16, 2023.
cbdMD CEO resigns; enters equity line with Keystone for up to 12.7M shares
Kevin MacDermott resigned as Principal Executive Officer and President effective Feb 26, 2023; no disagreement cited.
Shareholders elected four directors: Bakari Sellers, William F. Raines III, Scott G. Stephen, Dr. Sibyl Swift; ratified Cherry Bekaert as auditor.
Effective March 29, 2024, the Board of Directors (the "Board") of cbdMD, Inc. (the "Company") appointed Bradley Whitford, the Company's current Vice President of Finance, to serve as the Company's Chief Accounting Officer at the discretion of the Board.
On March 1, 2023, T. Ronan Kennedy agreed to serve as the Company’s Interim Chief Executive Officer and Principal Executive Officer and resigned as Chief Operating Officer of the Company in connection thereto.
On February 26, 2023, Kevin MacDermott notified cbdMD, Inc. (the “Company”) he was resigning as Principal Executive Officer and President of the Company, effective February26, 2023.
whereby he resigned as the Company’s Chief Executive Officer, member of the Board of Directors, employee, and all other capacities from the Company, effective June 11, 2022.
On June 11, 2022, Mr. Martin A. Sumichrast entered into a Separation Agreement (the “Separation Agreement”) with cbdMD, Inc. (the “Company”) and its subsidiaries whereby he resigned as the Company’s Chief Executive Officer, member of the Board of Directors, employee, and all other capacities from the Company, effective June 11, 2022.
On June 3, 2022 (the “Effective Date”) Scott G. Stephen, a member of the board of directors of cbdMD, Inc. (the “Company”) assumed the position of chairman of the board of directors of the Company as Martin A. Sumichrast agreed to vacate the position of chairman of the board of directors on the Effective Date.
Martin A. Sumichrast agreed to vacate the position of chairman of the board of directors on the Effective Date.
On the Effective Date, the Company entered into an Executive Employment Agreement with Kevin MacDermott pursuant to which Mr. MacDermott was hired to serve as the Company’s President.
On January 5, 2022 Sim Farar announced his resignation from our board of directors, effective immediately.
On December 1, 2021, John J. Wiesehan entered into a Separation and General Release (the “Separation Agreement”) with the cbdMD, Inc. (the “Company”) and its subsidiaries resigning as Chief Revenue Officer and all other capacities, effective December 1, 2021.
Mr. John J. Wiesehan III was appointed Chief Revenue Officer of the Company.
Max materiality 0.85 · Median 0.53 · Most common event other_material